shared-care-monitoring

To evaluate whether the COVID-19 pandemic affected the completion of shared care drug monitoring. It also considers whether any such effect was associated with other variables, such as patient demographics or comorbidities. The analysis covers all patients registered with a GP practice aged 18 years and over, who are currently prescribed currently prescribed Azathioprine, Methotrexate, or Leflunomide. Understanding the impact of COVID-19 on monitoring lays the foundation for further analysis of the health impact and recovery planning, and in the longer-term an analysis of whether current monitoring recommendations remain appropriate. Furthermore, understanding which factors underpin variance in resilience to deterioration in monitoring adherence may be valuable learning points, with a view to increasing the resilience of the population overall, and reducing health inequalities between the least and most resilient segments.